PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64684
- Registration Number
- NCT03572972
- Locations
- 🇰🇷
Korea University Hospital, Seoul, Korea, Republic of
A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccine
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 206
- Registration Number
- NCT03571607
- Locations
- 🇯🇵
National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan
🇯🇵Nagano Prefectural Shinshu Medical Center, Suzaka, Nagano, Japan
🇯🇵Kawasaki Municipal Hospital, Kawasaki, Kanagawa, Japan
Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
- Conditions
- Non-valvular Atrial Fibrillation
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 73989
- Registration Number
- NCT03570047
- Locations
- 🇯🇵
Pfizer Japan, Tokyo, Japan
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
- Conditions
- Genes, BRCA 1Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 202
- Registration Number
- NCT03565991
- Locations
- 🇺🇸
Northside Hospital, Inc. - GCS/Annex, Atlanta, Georgia, United States
🇺🇸Northside Hospital, Inc. - GCS/Northside, Atlanta, Georgia, United States
🇺🇸Atlanta Cancer Care - Atlanta, Atlanta, Georgia, United States
Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: MultivalentBiological: Prevnar 13
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 565
- Registration Number
- NCT03550313
- Locations
- 🇺🇸
Emmaus Research Center, Inc., Anaheim, California, United States
🇺🇸Madera Family Medical Group, Madera, California, United States
🇺🇸Mobile Pediatric Clinic, Mobile, Alabama, United States
Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India
- Conditions
- Vaccines
- Interventions
- Biological: 13vPnC
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 301
- Registration Number
- NCT03548337
- Locations
- 🇮🇳
Kanchi Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu, India
🇮🇳KEM Hospital Research Centre, Pune, Maharashtra, India
🇮🇳Bharati Vidyapeeth University Medical College, Pune, Maharashtra, India
Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Pfizer
- Registration Number
- NCT03546400
Lorlatinib Renal Impairment Study
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT03542305
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Prism Clinical Research, LLC, Saint Paul, Minnesota, United States
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 98
- Registration Number
- NCT03538743
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸Qps-Mra,Llc, South Miami, Florida, United States
A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 237
- Registration Number
- NCT03539601
- Locations
- 🇺🇸
Arlington Research Center, Inc., Arlington, Texas, United States
🇩🇪Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lubeck, Schleswig-holstein, Germany
🇵🇱Barbara Rewerska Diamond Clinic, Krakow, Malopolska, Poland